Thiadiazole compounds and uses thereof

A method of performing a phototherapy procedure, the method comprising:

• administering to a patient a biocompatible composition comprising an effective amount of a compound of Formula I and a biocompatible excipient to a target tissue;
• and
• exposing the administered compound at the target tissue to light of wavelength between 300 nm and 1200 nm sufficient to result in injury or death to cells at the target tissue, wherein the target tissue is a tumor or lesion, wherein:
• each of R1, R2, R3, and R4 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR5, —(CH2)aCO2R5, —(CH2)aNR5R6, —NR6COR5, —(CH2)aCONR5R6, —(CH2)aSR5, —(CH2)aSOR5, —(CH2)aSO2R5, —(CH2)aCON(R5)E, —(CH2)aN(R5)COE, —(CH2)aN(R5)CON(R6)E, or
• —(CH2)aN(R5)CSN(R6)E;
• or R1 and R2, R2 and R3, or R3 and R4, together with the carbon atoms to which they are attached, independently form alicyclic or heterocyclic structures, wherein a combination of R1 and R2, or a combination of R2 and R3, or a combination of R3 and R4 is —(CH2)bX(CH2)c—, —C(R7)═C(R8)—C(R9)═C(R10)—, —N═C(R7)—C(R8)═C(R9)—, —C(R7)═N—C(R8)═C(R9)—, —C(R7)═C(R8)—N═C(R9)—, —C(R7)═C(R8)—C(R9)═N—, —C(R7)═C(R8)—N(R9)—, —C(R7)═C(R8)—O—, —C(R7)═C(R8)—S—, —N═C(R7)—N(R8)—, —N═C(R7)—O—, —N═C(R7)—S—, —C(R7)═N—N(R8)—, —C(R7)═N—N(R8)—, —C(R7)═N—O—, —N═N—N(R8)—, —N═N—O—, or —N═N—S—;
• each of b and c independently varies from 0 to 3;
• X is —O—, —NR11—, —S—, —SO—, or —SO2—;
• each of R5 to R11 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxyalkyl, C1-C10 alkoxyalkyl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR12, —(CH2)aCO2R12, —(CH2)aNR12R13, —NR13COR12, —(CH2)aCONR12R13, —(CH2)aSR12, —(CH2)aSOR12, —(CH2)aSO2R12, —(CH2)aCON(R12)E, —(CH2)aN(R12)COE, —(CH2)aN(R12)CON(R13)E, or —(CH2)aN(R12)CSN(R13)E;
• a varies from 0 to 10;
• each of R12 and R13 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxyalkyl, C1-C10 alkoxyalkyl, C5-C10 heteroaryl, or C1-C10 acyl;
• and
• each E is independently hydrogen, a whole or fragmented somatostatin receptor binding molecule, a whole or fragmented ST receptor binding molecule, a whole or fragmented neurotensin receptor binding molecule, a whole or fragmented bombesin receptor binding molecule, a whole or fragmented CCK receptor binding molecule, a whole or fragmented steroid receptor binding molecule, or a whole or fragmented carbohydrate receptor binding molecule.

A method of performing a phototherapy procedure, the method comprising:

• administering to a patient a biocompatible composition comprising an effective amount of a compound of Formula I and a biocompatible excipient to a target tissue;
• and
• exposing the administered compound at the target tissue to light of wavelength between 300 nm and 1200 nm sufficient to result in injury or death to cells at the target tissue, wherein the target tissue is a tumor or lesion, wherein:
• each of R1, R2, R3, and R4 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR5, —(CH2)aCO2R5, —(CH2)aNR5R6, —NR6COR5, —(CH2)aCONR5R6, —(CH2)aSR5, —(CH2)aSOR5, —(CH2)aSO2R5, —(CH2)aCON(R5)E, —(CH2)aN(R5)COE, —(CH2)aN(R5)CON(R6)E, or
• —(CH2)aN(R5)CSN(R6)E;
• or R1 and R2, R2 and R3, or R3 and R4, together with the carbon atoms to which they are attached, independently form alicyclic or heterocyclic structures, wherein a combination of R1 and R2, or a combination of R2 and R3, or a combination of R3 and R4 is —(CH2)bX(CH2)c—, —C(R7)═C(R8)—C(R9)═C(R10)—, —N═C(R7)—C(R8)═C(R9)—, —C(R7)═N—C(R8)═C(R9)—, —C(R7)═C(R8)—N═C(R9)—, —C(R7)═C(R8)—C(R9)═N—, —C(R7)═C(R8)—N(R9)—, —C(R7)═C(R8)—O—, —C(R7)═C(R8)—S—, —N═C(R7)—N(R8)—, —N═C(R7)—O—, —N═C(R7)—S—, —C(R7)═N—N(R8)—, —C(R7)═N—N(R8)—, —C(R7)═N—O—, —N═N—N(R8)—, —N═N—O—, or —N═N—S—;
• each of b and c independently varies from 0 to 3;
• X is —O—, —NR11—, —S—, —SO—, or —SO2—;
• each of R5 to R11 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxyalkyl, C1-C10 alkoxyalkyl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR12, —(CH2)aCO2R12, —(CH2)aNR12R13, —NR13COR12, —(CH2)aCONR12R13, —(CH2)aSR12, —(CH2)aSOR12, —(CH2)aSO2R12, —(CH2)aCON(R12)E, —(CH2)aN(R12)COE, —(CH2)aN(R12)CON(R13)E, or —(CH2)aN(R12)CSN(R13)E;
• a varies from 0 to 10;
• each of R12 and R13 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxyalkyl, C1-C10 alkoxyalkyl, C5-C10 heteroaryl, or C1-C10 acyl;
• and
• each E is independently a whole or fragmented somatostatin receptor binding molecule, a whole or fragmented ST receptor binding molecule, a whole or fragmented neurotensin receptor binding molecule, a whole or fragmented bombesin receptor binding molecule, a whole or fragmented CCK receptor binding molecule, a whole or fragmented steroid receptor binding molecule, or a whole or fragmented carbohydrate receptor binding molecule.

A method of performing a phototherapy procedure, the method comprising:

• administering to a patient a biocompatible composition comprising an effective amount of a compound of Formula II and a biocompatible excipient to a target tissue;
• and
• exposing the administered compound at the target tissue to light of wavelength between 300 nm and 1200 nm sufficient to result in injury or death to cells at the target tissue, wherein the target tissue is a tumor or lesion, wherein:
• A is —(CH2)bX(CH2)c—, —C(R7)═C(R8)—C(R9)═C(R10)—, —N═C(R7)—C(R8)═C(R9)—, —C(R7)═N—C(R8)═C(R9)—, —C(R7)═C(R8)—N═C(R9)—, —C(R7)═C(R8)—C(R9)═N—, —C(R7)═C(R8)—N(R9)—, —C(R7)═C(R8)—O—, —C(R7)═C(R8)—S—, —N═C(R7)—N(R8)—, —N═C(R7)—O—, —N═C(R7)—S—, —C(R7)═N—N(R8)—, —C(R7)═N—N(R8)—, —C(R7)═N—O—, —N═N—O—, or —N═N—S—;
• each of R1 and R4 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR5, —(CH2)aCO2R5, —(CH2)aNR5R6, —NR6COR5, —(CH2)aCONR5R6, —(CH2)aSR5, —(CH2)aSOR5, —(CH2)aSO2R5, —(CH2)aCON(R5)E, —(CH2)aN(R5)COE, —(CH2)aN(R5)CON(R)E, or —(CH2)aN(R5)CSN(R6)E;
• each of b and c independently varies from 0 to 3;
• X is —O—, —NR11—, —S—, —SO—, or —SO2—;
• each of R5 to R11 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxyalkyl, C1-C10 alkoxyalkyl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR12, —(CH2)aCO2R12, —(CH2)aNR12R13, —NR13COR12, —(CH2)aCONR12R13, —(CH2)aSR12, —(CH2)aSOR12, —(CH2)aSO2R12, —(CH2)aCON(R12)E, —(CH2)aN(R12)COE, —(CH2)aN(R12)CON(R13)E, or —(CH2)aN(R12)CSN(R13)E;
• a varies from 0 to 10;
• each of R12 and R13 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxyalkyl, C1-C10 alkoxyalkyl, C5-C10 heteroaryl, or C1-C10 acyl;
• and
• each E is independently a whole or fragmented somatostatin receptor binding molecule, a whole or fragmented ST receptor binding molecule, a whole or fragmented neurotensin receptor binding molecule, a whole or fragmented bombesin receptor binding molecule, a whole or fragmented CCK receptor binding molecule, a whole or fragmented steroid receptor binding molecule, or a whole or fragmented carbohydrate receptor binding molecule.

A method of performing a phototherapy procedure, the method comprising:

• administering to a patient a biocompatible composition comprising an effective amount of a compound of Formula III and a biocompatible excipient to a target tissue;
• and
• exposing the administered compound at the target tissue to light of wavelength between 300 nm and 1200 nm sufficient to result in injury or death to cells at the target tissue, wherein the target tissue is a tumor or lesion, wherein:
• B is —(CH2)bX(CH2)c—, —C(R7)═C(R8)—C(R9)═C(R10)—, —N═C(R7)—C(R8)═C(R9)—, —C(R7)═N—C(R8)═C(R9)—, —C(R7)═C(R8)—N═C(R9)—, —C(R7)═C(R8)—C(R9)═N—, —C(R7)═C(R8)—N(R9)—, —C(R7)═C(R8)—O—, —C(R7)═C(R8)—S—, —N═C(R7)—N(R8)—, —N═C(R7)—O—, —N═C(R7)—S—, —C(R7)═N—N(R8)—, —C(R7)═N—N(R8)—, —C(R7)═N—O—, —N═N—N(R8)—, —N═N—O—, or —N═N—S—;
• each of R3 and R4 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR5, —(CH2)aCO2R5, —(CH2)aNR5R6, —NR6COR5, —(CH2)aCONR5R6, —(CH2)aSR5, —(CH2)aSOR5, —(CH2)aSO2R5,
• —(CH2)aCON(R5)E, —(CH2)aN(R5)COE, —(CH2)aN(R5)CON(R)E, or —(CH2)aN(R5)CSN(R6)E;
• each of b and c independently varies from 0 to 3;
• X is —O—, —NR11—, —S—, —SO—, or —SO2—;
• each of R5 to R11 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxyalkyl, C1-C10 alkoxyalkyl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR12, —(CH2)aCO2R12, —(CH2)aNR12R13, —NR13COR12, —(CH2)aCONR12R13, —(CH2)aSR12, —(CH2)aSOR12, —(CH2)aSO2R12, —(CH2)aCON(R12)E, —(CH2)aN(R12)COE, —(CHa)aN(R12)CON(R13)E, or —(CH2)aN(R12)CSN(R13)E;
• a varies from 0 to 10;
• each of R12 and R13 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxyalkyl, C1-C10 alkoxyalkyl, C5-C10 heteroaryl, or C1-C10 acyl;
• and
• each E is independently a whole or fragmented somatostatin receptor binding molecule, a whole or fragmented ST receptor binding molecule, a whole or fragmented neurotensin receptor binding molecule, a whole or fragmented bombesin receptor binding molecule, a whole or fragmented CCK receptor binding molecule, a whole or fragmented steroid receptor binding molecule, or a whole or fragmented carbohydrate receptor binding molecule.

A method of performing a phototherapy procedure, the method comprising:

• administering to a patient a biocompatible composition comprising an effective amount of a compound of Formula IV and a biocompatible excipient to a target tissue;
• and
• exposing the administered compound at the target tissue to light of wavelength between 300 nm and 1200 nm sufficient to result in injury or death to cells at the target tissue, wherein the target tissue is a tumor or lesion, wherein:
• D is —(CH2)bX(CH2)c—, —C(R7)═C(R8)—C(R9)═C(R10)—, —N═C(R7)—C(R8)═C(R9)—, —C(R7)═N—C(R8)═C(R9)—, —C(R7)═C(R8)—N═C(R9)—, —C(R7)═C(R8)—C(R9)═N—, —C(R7)═C(R8)—N(R9)—, —C(R7)═C(R8)—O—, —C(R7)═C(R8)—S—, —N═C(R7)—N(R8)—, —N═C(R7)—O—, —N═C(R7)—S—, —C(R7)═N—N(R8)—, —C(R7)═N—N(R8)—, —C(R7)═N—O—, —N═N—N(R8)—, —N═N—O—, or —N═N—S—;
• each of R1 and R2 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR5, —(CH2)aCO2R5, —(CH2)aNR5R6, —NR6COR5, —(CH2)aCONR5R6, —(CH2)aSR5, —(CH2)aSOR5, —(CH2)aSO2R5, —(CH2)aCON(R5)E, —(CH2)aN(R5)COE, —(CH2)aN(R5)CON(R)E, or —(CH2)aN(R5)CSN(R6)E;
• each of b and c independently varies from 0 to 3;
• X is —O—, —S—, —SO—, or
• each of R5 to R11 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxylakyl, C1-C10 alkoxyalkyl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR12, —(CH2)aCO2R12, —(CH2)aNR12R13, —NR13COR12, —(CH2)aCONR12R13, —(CH2)aSR12, —(CH2)aSOR12, —(CH2)aSO2R12, —(CH2)aCON(R12)E, —(CH2)aN(R12)COE, —(CH2)aN(R12)CON(R13)E, or —(CH2)aN(R12)CSN(R13)E;
• a varies from 0 to 10;
• each of R12 and R13 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxyalkyl, C1-C10 alkoxyalkyl, C5-C10 heteroaryl, or C1-C10 acyl;
• and
• each E is independently a whole or fragmented somatostatin receptor binding molecule, a whole or fragmented ST receptor binding molecule, a whole or fragmented neurotensin receptor binding molecule, a whole or fragmented bombesin receptor binding molecule, a whole or fragmented CCK receptor binding molecule, a whole or fragmented steroid receptor binding molecule, or a whole or fragmented carbohydrate receptor binding molecule.

A method of performing a phototherapy procedure, the method comprising:

• administering to a patient a biocompatible composition comprising an effective amount of a compound of Formula V and a biocompatible excipient to a target tissue;
• and
• exposing the administered compound at the target tissue to light of wavelength between 300 nm and 1200 nm sufficient to result in injury or death to cells at the target tissue, wherein the target tissue is a tumor or lesion, wherein:
• A is —(CH2)bX(CH2)c—;
• b is 2, and c is 1;
• X is —NR11—;
• R1 is hydrogen, C1-C10 alkyl, C5-C10 aryl, C5-C10 heteroaryl, C1-C10 acyl, halogen, nitro, cyano, —(CH2)aOR5, —(CH2)aCO2R5, —(CH2)aNR5R6, —NR6COR5, —(CH2)aCONR5R6, —(CH2)aSR5, —(CH2)aSOR5, —(CH2)aSO2R5, —(CH2)aCON(R5)E, —(CH2)aN(R5)COE, —(CH2)aN(R5)CON(R6)E, or —(CH2)aN(R5)CSN(R6)E;
• each of R5, R6, and R11 is independently hydrogen, C1-C10 alkyl, C5-C10 aryl, C1-C10 hydroxylakyl, or C1-C10 alkoxyalkyl;
• a varies from 0 to 10;
• and
• each E is independently a whole or fragmented somatostatin receptor binding molecule, a whole or fragmented ST receptor binding molecule, a whole or fragmented neurotensin receptor binding molecule, a whole or fragmented bombesin receptor binding molecule, a whole or fragmented CCK receptor binding molecule, a whole or fragmented steroid receptor binding molecule, or a whole or fragmented carbohydrate receptor binding molecule.